• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 52Scenario analyses for genotype 1 difference in SVR for shortened treatment duration using peginterferon alfa-2b and ribavirin combination therapy, compared with standard treatment – impact on cost-effectiveness estimates

SVR difference (%)Incremental cost (£)Incremental QALYICER
0−57990.03Shortened duration dominates
1−55870.00a6,249,786
3−5162−0.0682,347
5−4736−0.1238,053
a

The incremental QALY value of 0.00 appears in the table owing to rounding (to two decimal places). The value here is a very small negative number (−0.0009) hence the positive ICER.

The incremental QALY value of 0.00 appears in the table owing to rounding (to two decimal places). The value here is a very small negative number (−0.0009) hence the positive ICER.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.